Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pDONR221_SLC35B2 Citations (1)

Originally described in: The RESOLUTE consortium: unlocking SLC transporters for drug discovery.
Superti-Furga G, Lackner D, Wiedmer T, Ingles-Prieto A, Barbosa B, Girardi E, Goldmann U, Gurtl B, Klavins K, Klimek C, Lindinger S, Lineiro-Retes E, Muller AC, Onstein S, Redinger G, Reil D, Sedlyarov V, Wolf G, Crawford M, Everley R, ... Steppan CM Nat Rev Drug Discov. 2020 Jul;19(7):429-430. doi: 10.1038/d41573-020-00056-6.
PubMed Journal

Articles Citing pDONR221_SLC35B2

Articles
Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Dieter SM, Lovecchio D, Pataskar A, Zowada MK, Korner PR, Khalizieva A, van Tellingen O, Jager D, Glimm H, Agami R. Oncogene. 2022 Aug;41(32):3953-3968. doi: 10.1038/s41388-022-02400-z. Epub 2022 Jul 7. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.